Company Filing History:
Years Active: 2008
Title: Marc Saba El-Leil: Innovator in Cancer Research
Introduction
Marc Saba El-Leil is a notable inventor based in Montréal, Canada. He has made significant contributions to the field of cancer research, particularly in understanding predispositions to breast cancer. His innovative work has led to the development of methods that can potentially change the landscape of cancer diagnostics.
Latest Patents
Marc Saba El-Leil holds a patent for "Methods for determining a predisposition to develop breast adenocarcinoma or breast inflammatory carcinoma." This invention relates to a method for determining a patient's predisposition to develop cancer by detecting the EN2 gene or its expression product. The presence of at least one of these indicators is suggestive of a predisposition to breast cancer. Additionally, his patent includes antisense hybridization kits for determining predisposition to cancer and methods for reducing EN2 expression.
Career Highlights
Marc Saba El-Leil is affiliated with the Institut De Recherche Cliniques De Montréal, where he conducts his research. His work is pivotal in advancing the understanding of genetic factors in cancer development. With a focus on innovative methodologies, he aims to improve early detection and treatment options for breast cancer patients.
Collaborations
Some of his notable coworkers include Guy Sauvageau and Nicole Martin. Their collaborative efforts contribute to the ongoing research and development in the field of cancer diagnostics.
Conclusion
Marc Saba El-Leil's contributions to cancer research through his innovative patent highlight the importance of genetic understanding in disease predisposition. His work continues to pave the way for advancements in cancer diagnostics and treatment.